Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-02
2011-08-02
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S283000, C514S424000
Reexamination Certificate
active
07989421
ABSTRACT:
The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.
REFERENCES:
patent: 5028595 (1991-07-01), Soo
patent: 0 335 483 (1989-10-01), None
patent: 1 356 812 (2003-10-01), None
patent: WO 93/09120 (1993-05-01), None
patent: WO 01/39779 (2001-06-01), None
patent: WO 2004/085438 (2004-10-01), None
Torchio et al. Determination of the polar drug dimiracetam in human plasma and serum by column-switching high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications, vol. 666, Issue 1, Apr. 7, 1995, pp. 169-177.
White et al. Chemokines: integrators of pain and inflammation. Nat. Rev. Drug Discovery, 2005, 4: 834-888.
Vippagunta et al (Adv Drug Deliv Rev 48:3-26, 2001).
Hamza et al., “Management of chronic testicular pain with superior hypogastric plexus block,” Abstract, University of Virginia, Charlottesville, VA, Sympathetic Blocks (881).
Gimbel et al., “Impact of the lidocaine patch 5% on pain interference with quality of life..,” Abstract, Southern Drug Research, Birmingham, AL, Topical Analgesics (882).
Manville et al., “Effect of Levetiracetam on Fibromyalgia Pain..,” Abstract, University of California, Pain Clinical Research Center, San Francisco, CA, Anticonvulsants (883).
Kashyrnyy, S., “Dose-response evaluation of the analgesic effect of lamotrigine at the patients..,” Abstract, Vinnitsa Medical University, Vinnitsa, Ukraine (884).
Leighton et al., “k-Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat,” Br. J. Pharmacol., 1988, 93, pp. 553-560.
Irwin, “Comprehensive Observational Assessment: Ia. A Systematic, Quantitative Procedure for Assessing . . . ” Psychopharmacologia (Berl.) 13, 1968, pp. 222-257.
Shan et al., “New evidence for the involvement of spinal fractalkine receptor in pain facilitation and spinal glial activation in rat model . . . ,” Pain 129, 2007, pp. 64-75.
Pinza et al., “Synthesis and Pharmacological Activity of a Series of Dihydro-1H-pyrrolo[1,2-a] . . . ” Journal of Medicinal Chemistry, 1993, vol. 36, No. 26, pp. 4214-4220.
Kieburtz et al., “A randomized trail of amitriptyline and mexiletine for painful neuropathy in HIV infection,” Neurology, 1998, 51, pp. 1682-1688.
Altman et al., “Recommendations for the Medical Management of Osteoarthritis of the Hip and Knee,” Arthritis & Rheumatism, vol. 43, No. 9, Sep. 2000, pp. 1905-1915.
Bolay et al., “Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model,” Nature Medicine, vol. 8, No. 2, Feb. 2002, pp. 136-142.
Cavaletti et al., “Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat,” European Journal of Cancer 37, 2001, pp. 2457-2463.
Crofford et al., “Pregabalin for the Treatment of Fibromyalgia Syndrome,” Arthritis & Rheumatism, Vo. 52, No. 4, Apr. 2005, pp. 1264-1273.
Dubinsky et al., “Reversible Axonal Neuropathy from the Treatment of AIDS and Related Disorders with 2′,3′-dideoxycytidine,” Muscle & Nerve, Oct. 12, 1989, pp. 856-860.
Fernihough et al., “Pain related behaviour in two models of osteoarthritis in the rat knee,” Pain 112, 2004, pp. 83-93.
Hammack et al., “Phase III evaluation of nortriptyline for alleviation of symptoms of cisplatinum-induced peripheral neuropathy,” Pain 98, 2002, pp. 195-203.
Joseph et al., “Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat,” Pain 107, 2004, pp. 147-158.
Rao et al., “Efficacy of Gabapentin in the Management of Chemotherapy-induced Peripheral Neuropathy,” Cancer, Nov. 1, 2007, vol. 110, No. 9, pp. 2110-2118.
Maizels et al., “Antidepressants and Antiepileptic Drugs for Chronic Non-Cancer Pain,” American Family Physician, Feb. 1, 2005, vol. 71, No. 3, pp. 483-490.
Marchand et al., “Evidence for an antihyperalgesic effect of venlafaxine in vincristine-induced neuropathy in rat,” Brain Research 980, 2003, pp. 117-120.
Offenbaecher et al., “Current Trends in Neuropathic Pain Treatments with Special Reference to Fibromyalgia,” CNS Spectrums 10(3), 2005, pp. 285-297.
Polomano et al., “A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel,” Pain 94, 2001, pp. 293-304.
Rao et al., “Efficacy of Lamotrigine in the Management of Chemotherapy-induced Peripheral Neuropathy,” Cancer, Jun. 15, 2008, Vo. 112, No. 12, pp. 2802-2808.
Veneroni et al., “Anti-allodynic effect of NW-1029, a novel Na+ channel blocker, in experimental animal models of inflammatory and neuropathic pain,” Pain 102, 2003, pp. 17-25.
Farina Carlo
Ghelardini Carla
Petrillo Paola
Abelman ,Frayne & Schwab
Fetterolf Brandon
Neurotune AG
Pagonakis Anna
LandOfFree
Use of dimiracetam in the treatment of chronic pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of dimiracetam in the treatment of chronic pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of dimiracetam in the treatment of chronic pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2640247